Scarica l'app Stockscreener
0.5671
3.88%
-0.0229
Vor Biopharma Inc Borsa (VOR) Ultime notizie
Vor Biopharma CMO resigns to pursue new opportunity - Investing.com Australia
Vor Biopharma’s Chief Medical Officer Resigns - TipRanks
Vor Bio Advances in Clinical Trials and Secures Funding - TipRanks
Vor Biopharma stock plunges to 52-week low of $0.63 - Investing.com
Vor Biopharma stock plunges to 52-week low of $0.63 By Investing.com - Investing.com South Africa
Virtu Financial LLC Makes New $60,000 Investment in Vor Biopharma Inc. (NYSE:VOR) - Defense World
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely - Yahoo Finance
Vor Biopharma Inc. (NYSE:VOR) Receives Average Rating of “Buy” from Analysts - Defense World
Oppenheimer Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR) - MarketBeat
Vor Biopharma’s SWOT analysis: stock outlook amid AML treatment progress By Investing.com - Investing.com Canada
Vor Biopharma’s SWOT analysis: stock outlook amid AML treatment progress - Investing.com India
Vor Biopharma stock holds $6 target, Market Outperform rating By Investing.com - Investing.com South Africa
Vor Biopharma stock holds $6 target, Market Outperform rating - Investing.com India
Citizens JMP Reiterates Market Outperform Rating on Vor Biopharma, Inc. (VOR) - StreetInsider
Vor Biopharma (NYSE:VOR) Price Target Cut to $5.00 by Analysts at Stifel Nicolaus - The AM Reporter
Stifel Nicolaus Has Lowered Expectations for Vor Biopharma (NYSE:VOR) Stock Price - Defense World
Oppenheimer Reiterates “Outperform” Rating for Vor Biopharma (NYSE:VOR) - Defense World
Wedbush Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR) - Defense World
Stifel cuts Vor Biopharma stock target to $5, maintains Buy rating - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Skye Bioscience (SKYE) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Stifel cuts Vor Biopharma stock target to $5, maintains Buy rating By Investing.com - Investing.com South Africa
Vor Biopharma, Inc. (VOR) PT Lowered to $5 at Stifel - StreetInsider.com
Vor Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update - MarketScreener
Vor Biopharma (VOR) Files $350M Mixed Shelf - StreetInsider.com
Vor Biopharma Inc. SEC 10-K Report - TradingView
Vor Biopharma Inc. (VOR) reports earnings - Quartz
Vor Biopharma revises stock option exercise prices - MSN
Vor Biopharma Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
BenitecAnother Biopharma Rocket - Barchart
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts - Defense World
Vor Biopharma: Short On Cash, Too Much Uncertainty For Now (VOR) - Seeking Alpha
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq - ACCESS Newswire
Vor biopharma chief medical officer sells $3,162 in stock By Investing.com - Investing.com Canada
Vor biopharma chief medical officer sells $3,162 in stock - Investing.com India
Pre-market Movers: TNXP, INBS, SMMT, NDRA... - RTTNews
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials - Yahoo Finance
Vor biopharma’s chief medical officer sells $3,498 in stock By Investing.com - Investing.com Nigeria
Vor biopharma's chief medical officer sells $3,498 in stock - MSN
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross - MSN
Brokerages Set Vor Biopharma Inc. (NYSE:VOR) PT at $11.36 - MarketBeat
Following A 1.65% Weekly Incline, Is It Still A Buy For Nerdy Inc (NYSE: NRDY)? - Marketing Sentinel
Vor Biopharma Inc (NASDAQ: VOR) Stock Falling -15.06% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Should Energy Vault Holdings Inc (NYSE: NRGV) Rally After -60.12% Drop From High? - Marketing Sentinel
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL): How Can A Stock Be Up 7.83% Year To Date, But Still Loser - Marketing Sentinel
Vor Biopharma revises stock option exercise prices By Investing.com - Investing.com Canada
VOR Shares Experience Surge in Value - Knox Daily
Vor Biopharma Approves Stock Option Repricing Strategy - TipRanks
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):